Dataset from A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy

This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants.

本研究为一项III期全球性多中心开放标签双臂随机对照试验，旨在评估阿替利珠单抗（atezolizumab）对比化疗，用于经含铂治疗方案期间或之后出现疾病进展的局部晚期或转移性尿路上皮膀胱癌（UBC）受试者的疗效与安全性。研究治疗的预期持续时间基于持续临床获益，即直至疾病进展或出现不可接受的毒性反应。目标样本量为931名受试者。